First Report of Real-World Patient Characteristics and Treatment Patterns from POLARIS: Palbociclib in Hormone Receptor-Positive (HR+) Advanced Breast Cancer: A Prospective, Multicenter, Noninterventional Study.
J. L. Blum,S. L. McCune,M. A. Salkeni,D. M. Anderson,J. J. Migas,S. Lakhanpal,K. Patel,A. Bardia,G. Rocque,J. Wang,J. C. Cappelleri,G. Comstock,Y. Wang,D. Tripathy
DOI: https://doi.org/10.1093/annonc/mdy272.334
IF: 51.769
2018-01-01
Annals of Oncology
Abstract:Background: This study describes real-world use and population characteristics in HR+/HER2- advanced breast cancer (ABC) patients receiving palbociclib (PAL) in routine practice. Methods: This prospective, noninterventional study has a targeted enrollment of 1500 men and women from ∼110 sites. Site and patient data, monitored remotely for clarity/completeness, are collected from medical charts, physician surveys, and patient-reported outcomes; optional blood samples are collected during standard-of-care lab draws. Results: This is an interim report of the first 312 patients with completed baseline case report forms as of 9Mar18 from 66 US sites (data snapshot: 9Apr18). Most sites were community sites (79%) with 1-10 treating physicians (61%). Of 33 sites that use clinical pathways, 45% were based on NCCN and 42% on US Oncology guidelines. Selected patient characteristics are shown (Table). Before starting PAL at enrollment, 18% of patients received chemotherapy, 21% hormonal therapy, 11% radiotherapy, 4% surgical resection, and 66% had no prior ABC therapy. Overall, 72% of patients received PAL combination first-line, of whom 56% received PAL+letrozole or anastrozole, 41% PAL+fulvestrant, and 4% PAL+exemestane. Of patients receiving ≥second-line PAL, 46% received prior hormonal monotherapy, 43% prior chemotherapy alone, and 6% both.Table: 344PSelected patient demographic and clinical characteristicsAll Patients (N = 312)Age at study enrollment, yMedian (range)63 (29-92)Distribution, n (%)<4012 (3.8)40-5040 (12.8)51-69156 (50.0)70-7441 (13.1)75-8451 (16.3)≥8512 (3.8)Sex, n (%)Women308 (98.7)Men4 (1.3)Race, n (%)White256 (82.1)Black or African American46 (14.7)Other7 (2.2)Not reported3 (1.0)Hispanic/Latino ethnicity, n (%)31 (9.9)Insurance provider, n (%)Private insurance152 (48.7)Medicare133 (42.6)Medicaid14 (4.5)Uninsured5 (1.6)Pre/perimenopausal, n (%)40 (12.8)Distribution of disease-free interval, mo,*Disease-free interval was defined as the time from first diagnosis of breast cancer to onset of advanced/metastatic disease among patients with available initial breast cancer diagnosis dates and available date of first ABC diagnosis. n (%)<1297 (31.6)12-<2411 (3.6)24-<3625 (8.1)≥36174 (56.7)Number of present comorbidities by system organ class, median (minimum-maximum)4 (0-27)Musculoskeletal and connective tissue disorders, n (%)245 (78.5)Gastrointestinal disorders, n (%)225 (72.1)Metabolism and nutrition disorders, n (%)190 (60.9)Cardiac disorders, n (%)49 (15.7)* Disease-free interval was defined as the time from first diagnosis of breast cancer to onset of advanced/metastatic disease among patients with available initial breast cancer diagnosis dates and available date of first ABC diagnosis. Open table in a new tab Conclusions: This is the first large, prospective multicenter study assessing real-world use of a CDK4/6 inhibitor. In the first 312-patient cohort, most were treated at community sites. A heterogeneous real-world population received PAL, including elderly, premenopausal, African-American, Latino/Hispanic, and male patients not commonly represented in clinical trials. Hormone partners received with PAL included steroidal and nonsteroidal aromatase inhibitors or fulvestrant, predominantly first-line. Clinical trial identification: NCT03280303. Editorial acknowledgement: Editorial support was provided by Anny Wu, PharmD, of Complete Healthcare Communications, LLC (West Chester, PA), a CHC Group company, and funded by Pfizer Inc. Legal entity responsible for the study: Pfizer Inc. Funding: Pfizer Inc. Disclosure: J.L. Blum: Steering committee: Pfizer Inc. M.A. Salkeni: Contracted research funding as study PI via author’s institution: West Virginia University. J.J. Migas, J. Wang: Contracted research: Pfizer Inc. A. Bardia: Advisory board: Novartis, Pfizer Inc, Spectrum Pharma. G. Rocque: Steering committee: Pfizer Inc; Contracted research: Genentech, Carevive, Pack Health, Medscape. J.C. Cappelleri, G. Comstock, Y. Wang: Employee and stockholder: Pfizer Inc. D. Tripathy: Steering committee: Novartis, Pfizer Inc; Contracted research: Novartis, Pfizer Inc. All other authors have declared no conflicts of interest.